Study uncovers an additional strategy for targeting treatment-resistant prostate cancer

May 2, 2017
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

Prostate cancer cells depend on signaling through the androgen receptor (AR) to grow and survive. Many anti-cancer therapies that target ARs are initially successful in patients, including a class of drugs known as CYP17A1 inhibitors, which interfere with AR signaling by blocking the synthesis of androgen. However, over time, adaptations to AR expression and function lead to treatment resistance and disease relapse.

Recently, the observation that a CYP17A1 inhibitor, seviteronel, effectively treated a patient's prostate cancer without actually lowering androgen levels led researchers at Duke University to further investigate the drug's therapeutic activity.

In a study published this week in the JCI, a team led by Donald McDonnell found that many CYP17A1 inhibitors also function as competitive AR antagonists, indicating a more complex and potentially more effective role for the drug in treating prostate cancer. The researchers then demonstrated CYP17A1 inhibitors that act at AR receptors can inhibit the growth of prostate tumor cells expressing a treatment-resistant AR mutation.

These findings provide insights into a mechanism that may lead to the development of more effective therapies for treatment-resistant .

Explore further: A new method for prostate cancer imaging

More information: John D. Norris et al, Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer, Journal of Clinical Investigation (2017). DOI: 10.1172/JCI87328

Related Stories

A new method for prostate cancer imaging

July 21, 2016
Prostate cancer is one of the most common cancers in men. Tumor growth is critically regulated by the androgen receptor, and treatment strategies to lower androgens, such as testosterone, are a mainstay of clinical treatment. ...

New molecules may offer treatment option for some aggressive prostate cancers

April 2, 2017
Novel molecules called selective androgen receptor degraders (SARDs) may offer the next generation of treatment options for advanced prostate cancer, a new industry-sponsored study reports. The results of this research will ...

Compound shows promise as next-generation prostate cancer therapy

August 8, 2016
In the search for new ways to attack recurrent prostate cancer, researchers at Duke Health report that a novel compound appears to have a unique way of blocking testosterone from fueling the tumors in mice.

Castration-resistant prostate cancer cell growth impeded by endostatin

March 10, 2017
Failure of hormone deprivation therapy, which is used to slow prostate cancer in patients, leads to castration-resistant prostate cancer, a lethal form of advanced disease with limited treatment options.

New target for prostate cancer resistant to anti-hormone therapies

April 23, 2014
Prostate cancer becomes deadly when anti-hormone treatments stop working. Now a new study suggests a way to block the hormones at their entrance.

Combination immunotherapy effective for advanced prostate cancer

March 9, 2017
Advanced prostate cancer resistant to castration therapy appears to respond well to a combination of immune checkpoint blockades and treatments that target certain immune-busting cells commonly associated with poor patient ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.